Subsequent trials, including CheckMate-648 (8), JUPITER-06 (9), and ASTRUM-007 (10), have further validated the broad applicability of anti-PD-1-based immunochemotherapy in advanced esophageal cancer. Here, PDCD1 is linked to esophageal cancer.